| Methods |
1‐week washout period (for patients previously treated with antihypertensive therapy); 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 100‐115 mm Hg (which differed by less than 10 mm Hg from that observed on the previous visit) after run‐in; 6‐week double‐blind treatment |
| Participants |
Trandolapril 0.5‐2 mg: n=85; baseline SBP/DBP not reported;
Placebo: n=30; baseline SBP/DBP not reported |
| Interventions |
Trandolapril 0.5 mg once daily;
Trandolapril 1 mg once daily;
Trandolapril 2 mg once daily;
Placebo;
administered with or immediately after breakfast |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Adjusted and non‐adjusted BP data reported; non‐adjusted BP entered in Revman; BP change reported, SD of change not reported; 95% confidence interval of change reported; endpoint BP and SD not reported; calculated SD of change from 95% CI of change; BP data from Table 1, p. 493; Jadad score=3; funding source= Knoll AG |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
